107 related articles for article (PubMed ID: 32643734)
1. Direct visualization of the conformational change of FUS/TLS upon binding to promoter-associated non-coding RNA.
Hamad N; Watanabe H; Uchihashi T; Kurokawa R; Nagata T; Katahira M
Chem Commun (Camb); 2020 Aug; 56(64):9134-9137. PubMed ID: 32643734
[TBL] [Abstract][Full Text] [Related]
2. RNA sequence and length contribute to RNA-induced conformational change of TLS/FUS.
Hamad N; Mashima T; Yamaoki Y; Kondo K; Yoneda R; Oyoshi T; Kurokawa R; Nagata T; Katahira M
Sci Rep; 2020 Feb; 10(1):2629. PubMed ID: 32060318
[TBL] [Abstract][Full Text] [Related]
3. Residue-by-Residue View of In Vitro FUS Granules that Bind the C-Terminal Domain of RNA Polymerase II.
Burke KA; Janke AM; Rhine CL; Fawzi NL
Mol Cell; 2015 Oct; 60(2):231-41. PubMed ID: 26455390
[TBL] [Abstract][Full Text] [Related]
4. Arginine methylation of translocated in liposarcoma (TLS) inhibits its binding to long noncoding RNA, abrogating TLS-mediated repression of CBP/p300 activity.
Cui W; Yoneda R; Ueda N; Kurokawa R
J Biol Chem; 2018 Jul; 293(28):10937-10948. PubMed ID: 29784880
[TBL] [Abstract][Full Text] [Related]
5. Intrinsically disordered RGG/RG domains mediate degenerate specificity in RNA binding.
Ozdilek BA; Thompson VF; Ahmed NS; White CI; Batey RT; Schwartz JC
Nucleic Acids Res; 2017 Jul; 45(13):7984-7996. PubMed ID: 28575444
[TBL] [Abstract][Full Text] [Related]
6. The role of ATP in solubilizing RNA-binding protein fused in sarcoma.
Aida H; Shigeta Y; Harada R
Proteins; 2022 Aug; 90(8):1606-1612. PubMed ID: 35297101
[TBL] [Abstract][Full Text] [Related]
7. Conformational fluctuations and phases in fused in sarcoma (FUS) low-complexity domain.
Thirumalai D; Kumar A; Chakraborty D; Straub JE; Mugnai ML
Biopolymers; 2024 Mar; 115(2):e23558. PubMed ID: 37399327
[TBL] [Abstract][Full Text] [Related]
8. Intrinsically disordered sequences enable modulation of protein phase separation through distributed tyrosine motifs.
Lin Y; Currie SL; Rosen MK
J Biol Chem; 2017 Nov; 292(46):19110-19120. PubMed ID: 28924037
[TBL] [Abstract][Full Text] [Related]
9. Promoter-associated long noncoding RNAs repress transcription through a RNA binding protein TLS.
Kurokawa R
Adv Exp Med Biol; 2011; 722():196-208. PubMed ID: 21915790
[TBL] [Abstract][Full Text] [Related]
10. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription.
Wang X; Arai S; Song X; Reichart D; Du K; Pascual G; Tempst P; Rosenfeld MG; Glass CK; Kurokawa R
Nature; 2008 Jul; 454(7200):126-30. PubMed ID: 18509338
[TBL] [Abstract][Full Text] [Related]
11. Non-coding RNA suppresses FUS aggregation caused by mechanistic shear stress on pipetting in a sequence-dependent manner.
Hamad N; Yoneda R; So M; Kurokawa R; Nagata T; Katahira M
Sci Rep; 2021 May; 11(1):9523. PubMed ID: 33947944
[TBL] [Abstract][Full Text] [Related]
12. Molecular interactions underlying liquid-liquid phase separation of the FUS low-complexity domain.
Murthy AC; Dignon GL; Kan Y; Zerze GH; Parekh SH; Mittal J; Fawzi NL
Nat Struct Mol Biol; 2019 Jul; 26(7):637-648. PubMed ID: 31270472
[TBL] [Abstract][Full Text] [Related]
13. Fused in sarcoma/translocated in liposarcoma: a multifunctional DNA/RNA binding protein.
Yang S; Warraich ST; Nicholson GA; Blair IP
Int J Biochem Cell Biol; 2010 Sep; 42(9):1408-11. PubMed ID: 20541619
[TBL] [Abstract][Full Text] [Related]
14. G-quadruplex binding ability of TLS/FUS depends on the β-spiral structure of the RGG domain.
Yagi R; Miyazaki T; Oyoshi T
Nucleic Acids Res; 2018 Jul; 46(12):5894-5901. PubMed ID: 29800261
[TBL] [Abstract][Full Text] [Related]
15. TDP-43 and FUS/TLS: sending a complex message about messenger RNA in amyotrophic lateral sclerosis?
Strong MJ; Volkening K
FEBS J; 2011 Oct; 278(19):3569-77. PubMed ID: 21810174
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD).
Lourenco GF; Janitz M; Huang Y; Halliday GM
Neurobiol Dis; 2015 Oct; 82():445-454. PubMed ID: 26220395
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of the FUS low-complexity domain disrupts phase separation, aggregation, and toxicity.
Monahan Z; Ryan VH; Janke AM; Burke KA; Rhoads SN; Zerze GH; O'Meally R; Dignon GL; Conicella AE; Zheng W; Best RB; Cole RN; Mittal J; Shewmaker F; Fawzi NL
EMBO J; 2017 Oct; 36(20):2951-2967. PubMed ID: 28790177
[TBL] [Abstract][Full Text] [Related]
18. Selective interactions of hnRNP M isoforms with the TET proteins TAF15 and TLS/FUS.
Marko M; Leichter M; Patrinou-Georgoula M; Guialis A
Mol Biol Rep; 2014; 41(4):2687-95. PubMed ID: 24474660
[TBL] [Abstract][Full Text] [Related]
19. Proto-oncoprotein TLS/FUS is associated to the nuclear matrix and complexed with splicing factors PTB, SRm160, and SR proteins.
Meissner M; Lopato S; Gotzmann J; Sauermann G; Barta A
Exp Cell Res; 2003 Feb; 283(2):184-95. PubMed ID: 12581738
[TBL] [Abstract][Full Text] [Related]
20. ALS-causative mutations in FUS/TLS confer gain and loss of function by altered association with SMN and U1-snRNP.
Sun S; Ling SC; Qiu J; Albuquerque CP; Zhou Y; Tokunaga S; Li H; Qiu H; Bui A; Yeo GW; Huang EJ; Eggan K; Zhou H; Fu XD; Lagier-Tourenne C; Cleveland DW
Nat Commun; 2015 Jan; 6():6171. PubMed ID: 25625564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
